NewcelX shares surge 13.22% intraday after updated corporate presentation highlights sharpened Type 1 Diabetes cell therapy focus and leadership expansion.

NewcelX surged 13.22% intraday after announcing an updated corporate presentation emphasizing its sharpened strategic focus on Type 1 Diabetes cell therapy, recent scientific progress, and new Scientific Advisory Board and leadership appointments. The presentation, released ahead of spring 2026 investor and partnering conferences, highlights the company’s clinical development priorities and regenerative medicine approach to restoring insulin production. Strengthened expertise in cell therapy and commercialization, coupled with plans to engage with partners and investors at major events like BIO-Europe Spring, reinforced investor confidence in the firm’s near- and mid-term value-creation milestones. Management also outlined expanded collaboration opportunities and pipeline advancements, positioning NewcelX to capitalize on its clinical-stage focus in a high-growth therapeutic area.